Post by Lea Ruge

Excited to share our latest work, now published in AACR Journals, Clinical Cancer Research. In this real-world cohort study from Cologne, we analyzed 365 patients with KRAS Q61-mutated NSCLC — the largest dataset on this rare but biologically distinct subgroup to date. Our findings highlight marked differences between the predominant subtypes Q61H and Q61L, particularly in co-mutational landscape (STK11, KEAP1, TP53) and clinical outcomes. Immunotherapy-based regimens were associated with more favorable outcomes, especially in patients with high PD-L1 expression — with hopefully more to follow from national data. Thank you to all co-authors and collaborators, and to Jürgen Wolf and Matthias Scheffler for their support. Full text (free access): https://lnkd.in/emPVjSrk